Related Experiment Video
Updated: May 15, 2025
Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
Insights into Pediatric GATA2-Related MDS: Unveiling Challenges in Clinical Practice
Andra Daniela Marcu1,2, Ana Maria Bica1,2, Cristina Georgiana Jercan1,2
1Faculty of Medicine, University of Medicine and Pharmacy Carol Davila, 020021 Bucharest, Romania.
Insights
GATA2-related myelodysplastic syndrome (GATA2-MDS) carries a high risk of leukemia. Hematopoietic stem cell transplantation (HSCT) is curative but challenging, with post-transplant cyclophosphamide (PT/Cy) showing promise.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- GATA2-related myelodysplastic syndrome (GATA2-MDS) is a genetic predisposition with a significant risk of leukemic transformation.
- Key features include monosomy 7, recurrent infections, immunodeficiency, and lymphedema, with prognosis worsening with age.
Purpose of the Study:
- To systematically review the literature on GATA2-MDS, focusing on disease characteristics, diagnosis, management, and outcomes of hematopoietic stem cell transplantation (HSCT).
- To present two pediatric GATA2-MDS cases illustrating clinical and therapeutic challenges.
Main Methods:
- Systematic literature review of eight cohort and case-control studies.
- Inclusion of two pediatric GATA2-MDS cases for real-world clinical insights.
Main Results:
- HSCT is the only curative treatment for GATA2-MDS, but is associated with high rates of graft-versus-host disease (GvHD), unique complications (neurological, thrombotic, infectious), and transplant-related mortality (TRM).
- Post-transplant cyclophosphamide (PT/Cy) strategies may improve survival by reducing GvHD.
- Case studies highlighted rapid disease progression, leukemic transformation, novel mutations, and HSCT complications.
Conclusions:
- Collaborative research is essential to improve understanding and management of GATA2-related myeloid malignancies.
- Further investigation into novel therapeutic strategies and optimizing HSCT protocols, including PT/Cy, is warranted.
Abstract:
Background:GATA2-related myelodysplastic syndrome (GATA2-MDS) is a unique predisposition syndrome with a high risk of leukemic transformation. This systematic review synthesizes current literature and presents two illustrative pediatric GATA2-MDS cases. Methods: Data retrieval from eight cohort and case-control studies provides comprehensive analysis on disease features, diagnostic complexities, management, and outcomes related to hematopoietic stem cell transplantation (HSCT) in GATA2-related myeloid malignancies. Additionally, two pediatric cases are included to exemplify clinical and therapeutic challenges in real-world setting. Results: The literature data demonstrates high incidence of monosomy 7, and recurrent infections as the most common clinical feature, followed by immunodeficiency and lymphedema. Prognosis clearly worsens with age and HSCT remains the only curative treatment. GATA2 patients undergoing HSCT experience high rates of graft versus host disease (GvHD) as well as unique neurological, thrombotic, and infectious complications. Transplant-related mortality (TRM) is linked to GvHD and infections. Post-transplant cyclophosphamide (PT/Cy) strategies seem to improve survival by reducing GvHD incidence. Overall survival (OS) remains variable across groups. The first case presents rapid disease progression to pulmonary alveolar proteinosis (PAP) and leukemic transformation, further developing severe HSCT complications. The second case addresses novel GATA2 mutation and raises concerns regarding alternative prophylactic and therapeutic strategies in transplant setting. Conclusions: Collaborative efforts aim to enhance understandings of GATA2-related myeloid malignancies and guide towards more effective management approaches.
